Abstract
Research into cancer over the past 10 years has diverged enormously, partly based on the large number of new technologies that are now at our finger tips. With areas of cancer research so disparate, it is not always easy to identify where the next new findings and therapies might come from. With this in mind, we asked four leading cancer researchers from around the world what, in their opinion, we have learnt over the past 10 years and how we should progress in the next 10 years.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Ngoma, T. World Health Organization cancer priorities in developing countries. Ann. Oncol. 17, viii9–viii14 (2006).
Moore, P. S. & Chang, Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nature Rev. Cancer 10, 878–889 (2010).
Stratton, M. R. Exploring the genomes of cancer cells: progress and promise. Science 331, 1553–1558 (2011).
Broderick, P. et al. Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res. 69, 6633–6641 (2009).
Teodoridis, J. M., Hardie, C. & Brown, R. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett. 268, 177–186 (2008).
de Bono, J. S. & Ashworth, A. Translating cancer research into targeted therapeutics. Nature 467, 543–549 (2010).
Quatrale, A. E. et al. EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front. Biosci. 16, 1962–1972 (2011).
Collins, F. S. and A. D. Barker . Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci. Am. 296, 50–57 (2007).
Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
Wood, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108–1113 (2007).
Fanidi, A. et al. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359, 554–555 (1992).
Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).
Collado, M. & Serrano, M. Senescence in tumours: evidence from mice and humans. Nature Rev. Cancer 10, 51–57 (2010).
Degenhardt, K. et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10, 51–64 (2006).
Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431–435 (2010).
Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209–221 (2010).
Poulikakos, P. I. et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427–430 (2010).
Villa, L. L. HPV prophylactic vaccination: the first years and what to expect from now. Cancer Lett. 305, 106–112 (2011).
Human papillomaviruses. IARC Monogr. Eval Carcinog. Risks Hum. 64, 1–378 (1995).
Garzon, R., Marcucci, G. & Croce, C. M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nature Rev. Drug Discov. 9, 775–789 (2010).
McDermott, U., Downing, J. R. & Stratton, M. R. Genomics and the continuum of cancer care. N. Engl. J. Med. 364, 340–350 (2011).
Beatson, G. On the treatment of inoperable cases of carinoma of the mamma: suggesitons for a new method of treatment with illustrative cases. Lancet 148, 104–107 (1896).
Vultur, A., Villanueva, J. & Herlyn, M. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin. Cancer Res. 17, 1658–1663 (2011).
Yen, K. E., Bittinger, M. A., Su, S. M. & Fantin, V. R. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 29, 6409–6417 (2010).
Brough, R., Frankum, J. R., Costa-Cabral, S., Lord, C. J. & Ashworth, A. Searching for synthetic lethality in cancer. Curr. Opin. Genet. Dev. 21, 34–41 (2011).
Poulikakos, P. I. & Rosen, N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 19, 11–15 (2011).
Workman, P. & de Bono, J. Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine. Curr. Opin. Pharmacol. 8, 359–362 (2008).
Carden, C. P., Banerji, U., Kaye, S. B., Workman, P. & de Bono, J. S. From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin. Pharmacol. Ther. 85, 131–133 (2009).
Chin L, H. W., Getz, G & Meyerson, M. Making sense of cancer genomic data. Genes Dev. 25, 534–555 (2011).
The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).
Schreiber, S. L. et al. Towards patient-based cancer therapeutics. Nature Biotech. 28, 904–906 (2010).
Stommel, J. M. et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287–290 (2007).
Campbell, P. J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109–1113 (2010).
Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114–1117 (2010).
Shackleton, M. et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138, 822–829 (2009).
Tuveson, D. A. et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20, 5054–5058 (2001).
Solimini, N. L. et al. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130, 986–988 (2007).
Cairns, R. A. et al. Regulation of cancer cell metabolism. Nature Rev. Cancer 11, 85–95 (2011).
Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).
Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
DeBerardinis, R. J., Sayed, N., Ditsworth, D. & Thompson, C. B. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 18, 54–61 (2008).
McAllister, S. S. & Weinberg, R. A. Tumor-host interactions: a far-reaching relationship. J. Clin. Oncol. 28, 4022–4028 (2010).
Wilson, A. J. Inhibition of protein-protein interactions using designed molecules. Chem. Soc. Rev. 38, 3289–3300 (2009).
Acknowledgements
M.E. is a research fellow of the National Health and Medical Research Council Australia. Y.C. thanks Z. Dong and A.M. Bode, The Hormel Institute, University of Minnesota, USA.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Rights and permissions
About this article
Cite this article
Cao, Y., DePinho, R., Ernst, M. et al. Cancer research: past, present and future. Nat Rev Cancer 11, 749–754 (2011). https://doi.org/10.1038/nrc3138
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc3138